全文获取类型
收费全文 | 690960篇 |
免费 | 44782篇 |
国内免费 | 1294篇 |
专业分类
耳鼻咽喉 | 9340篇 |
儿科学 | 21668篇 |
妇产科学 | 16963篇 |
基础医学 | 108039篇 |
口腔科学 | 18064篇 |
临床医学 | 61737篇 |
内科学 | 131180篇 |
皮肤病学 | 14803篇 |
神经病学 | 53910篇 |
特种医学 | 24628篇 |
外国民族医学 | 76篇 |
外科学 | 103302篇 |
综合类 | 10812篇 |
现状与发展 | 3篇 |
一般理论 | 348篇 |
预防医学 | 52271篇 |
眼科学 | 16878篇 |
药学 | 52168篇 |
中国医学 | 1212篇 |
肿瘤学 | 39634篇 |
出版年
2021年 | 5888篇 |
2019年 | 6226篇 |
2018年 | 8268篇 |
2017年 | 6044篇 |
2016年 | 6884篇 |
2015年 | 7918篇 |
2014年 | 11062篇 |
2013年 | 17308篇 |
2012年 | 24038篇 |
2011年 | 26315篇 |
2010年 | 15000篇 |
2009年 | 13963篇 |
2008年 | 25016篇 |
2007年 | 26766篇 |
2006年 | 26527篇 |
2005年 | 26302篇 |
2004年 | 25414篇 |
2003年 | 24195篇 |
2002年 | 23710篇 |
2001年 | 25655篇 |
2000年 | 26321篇 |
1999年 | 22225篇 |
1998年 | 7739篇 |
1997年 | 6720篇 |
1996年 | 6737篇 |
1995年 | 6201篇 |
1994年 | 5761篇 |
1992年 | 16834篇 |
1991年 | 17319篇 |
1990年 | 17313篇 |
1989年 | 16654篇 |
1988年 | 15466篇 |
1987年 | 15174篇 |
1986年 | 14467篇 |
1985年 | 13908篇 |
1984年 | 10853篇 |
1983年 | 9433篇 |
1982年 | 6188篇 |
1979年 | 10227篇 |
1978年 | 7771篇 |
1977年 | 6586篇 |
1976年 | 6326篇 |
1975年 | 6973篇 |
1974年 | 8237篇 |
1973年 | 7622篇 |
1972年 | 7348篇 |
1971年 | 6963篇 |
1970年 | 6408篇 |
1969年 | 6106篇 |
1968年 | 5721篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
101.
102.
103.
I K Shkhvatsabaia A N Kravchenko P V Avdonin M Iu Men'shikov A A Nekrasova 《Kardiologiia》1988,28(5):72-77
Platelet activation factor (PAF)-, ADP and vasopressin-induced increments of platelet Ca2+ concentration were measured by quin-2 in 64 patients with essential hypertension and 16 normal donors. Basal concentration of free Ca2+ was 87 +/- 4 nM in donors, 106 +/- 5 nM in patients with labile hypertension (LH) and 122 +/- 6 nM in those with stable hypertension (SH) (p less than 0.01). PAF, ADP and vasopressin, added to platelets, increased [Ca]in by 448 +/- 58, 397 +/- 66, and 277 +/- 50 nM, respectively, in the donors, by 473 +/- 57, 479 +/- 54 and 195 +/- 32 nM, in LH patients, and by 607 +/- 85, 584 +/- 73 and 245 +/- 41 nM in SH patients. There were no significant variations between the three samples, using the ANOVA test. In 20 patients, whose both parents had essential hypertension, [Ca]in increment was 738 +/- 8 nM for PAF, 682 +/- 90 nM for ADP, and 320 +/- 61 nM for vasopressin. In 19 patients, who admitted to no essential hypertension in the family, these parameters were significantly lower: 310 +/- 40 nM for PAF, 389 +/- 61 nM for ADP, and 147 +/- 26 nM for vasopressin. The demonstrated changes may be making an important contribution to the maintenance of elevated vascular tone and provide an evidence in favor of a genetically-predetermined EH variety. 相似文献
104.
R. P. Heaney T. M. Zizic I. Fogelman W. P. Olszynski P. Geusens C. Kasibhatla N. Alsayed G. Isaia M. W. Davie C. H. Chesnut III 《Osteoporosis international》2002,13(6):501-505
Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy
in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined.
We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical
trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score =–3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n= 328) or placebo (n= 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up
to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4%
in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval
37% to 90%; P= 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were
stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of
70%, 95% CI 8% to 90%; P= 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P= 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women
with osteoporosis, with a similar magnitude of effect early and late after the menopause.
Received: 12 September 2001 / Accepted: 11 December 2001 相似文献
105.
Oral allergy syndrome induced by spinach 总被引:1,自引:1,他引:0
I. Sanchez F. Rodriguez J. L. Garcia-Abujeta L. Fernandez D. Quiñones D. Martin-Gil 《Allergy》1997,52(12):1245-1246
106.
Congenital intermaxillary fusion is a rare anomaly. Combination of the anomaly with any type of facial cleft is extremely rare. Death in a majority of these patients as a result of feeding and aspiration problems in early life may have caused the reports to be limited. In this article a 5-year-old patient, probably the first in the literature having Tessier type VI-VII facial cleft combination associated with bimaxillary fusion and anophthalmia on the right side, is presented. The patient has survived on fluid meal through a very small opening for 5 years. The features of the case are presented, and the time and method of the management of such a rare anomaly are discussed with a review of the literature. 相似文献
107.
M. NEUBRAND I. GREINWALD H. LOBENTANZER G. PAUMGARTNER H. HERMEKING T. SAUERBRUCH 《European journal of clinical investigation》1997,27(3):234-241
Efficient fragmentation is the most important prerequisite for successful treatment of gallstones by extracorporeally induced shock waves. No data are available on the amount of energy necessary for stone disintegration and on the threshold energy below which no further fragmentation occurs. We therefore performed an in vitro investigation on human cholesterol gallstones to elucidate physical laws governing shock-wave lithotripsy. First, the focal pressure of the lithotripter was measured to calculate the energy traversing a stone. Second, 96 gallstones from 16 gall bladders were analysed with respect to physicochemical composition, radiological features and ultrasound before fragmentation was performed. Energy for stone disintegration was constant within each stone family but varied between 4.6 J mL?1 and 36.8 J mL?1 in different families. This energy correlated linearly with stone volume. None of the radiological and physicochemical factors revealed a clear-cut correlation of the different energies necessary for similar stone disintegration. The threshold energy differed between 0.26 mJ and 1.04 mJ per pulse. In conclusion, stone volume was the best parameter predicting stone fragmentation. However, in cholesterol stones with a similar composition the required energy per volume varies considerably together with the threshold energy. Radiological and ultrasound parameters appear to be of minor importance in explaining these differences. 相似文献
108.
109.
J.I. Smedberg E. Lothigius I. Bodin A. Frykholm K. Nilner 《Clinical oral implants research》1993,4(1):39-46
In order to satisfy the need to restore the aesthetics, phonetics and comfort and to facilitate optimal hygiene procedures, 20 edentulous patients were treated with a new concept of overdenture therapy on implants ad modum Brånemark. After 24±3.5 months the patients were re‐examined. They were asked to answer a questionnaire and use a Visual Analogue Scale (VAS) to give their opinion on the prosthetic treatment. The results indicate that an implant‐retained overdenture in the maxilla with this design can satisfy the patients needs in aesthetics, phonetics and comfort and can 1 facilitate oral hygiene measures. 相似文献
110.
Herbert Radner Yosuf El-Shabrawi Robert H. Eibl Oliver Brüstle Lukas Kenner Paul Kleihues Otmar D. Wiestler 《Acta neuropathologica》1993,86(5):456-465
Introduction into fetal rat brain cells of a replication-defective retroviral vector harboring v-Ha-ras and v-gag-myc rapidly causes the induction of highly malignant undifferentiated neuroectodermal tumors following transplantation into the brains of syngeneic hosts [Wiestler, et al. (1992) Cancer Res. 52: 3760–3767]. In the present study, we have investigated the modulating effect of the developmental stage of neural target cells and of the dose of the retroviral vector used in the grafting experiments. Exposure of fetal cells from embryonic day (E)12 or E14 produced a 100% incidence of malignant neuroectodermal tumors which led to the death of recipient animals after a median latency period of 32 days. A 100-fold reduction of the virus dose from 2.062×106 to 2.062×104 focus-forming units/ml resulted in a lower tumor incidence of 25%. Of six neural grafts exposed to v-Ha-ras and v-myc at E16, only one showed evidence of tumorigenesis (low-grade astrocytoma and hemangioma). All other transplants were morphologically normal for observation periods of 26 weeks, indicating a marked loss of transforming activity of ras and myc in more advanced stages of brain development. In retrovirus-exposed donor cells which caused the development of neural tumors in recipient rats, malignant transformation was also evident during culture in vitro, usually after 9–12 days. Oncogene complementation was also studied in the newborn rat brain. After microinjection of the retroviral vector into the brain at postnatal day (P)0, P1 and P3, 5 out of 20 animals (25%) developed a total of seven brain tumors. Histopathologically, three of these neoplasms were malignant neuroectodermal tumors which, in contrast to those induced in fetal brain transplants showed evidence of focal glial and/or neuronal differentiation. In addition, we observed one oligodendroglioma, two hemangiomas and a malignant hemangioendothelioma. These data indicate that neural precursor cells and endothelia of the rat brain represent the major target cells for the complementary action of ras and myc and that the use of target cells from later developmental stages (E16 and postnatal) leads to the induction of both primitive and more differentiated neoplasms.These studies were supported by the Fonds zur Förderung der wissenschaftlichen Forschung in Österreich (Erwin Schrödinger fellowship, JO501-MED), by the Swiss National Science Foundation and by the Cancer League of the Kanton of Zürich 相似文献